Trevi Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Trevi Therapeutics, Inc. (TRVI) reported Debt Securities, Available-for-sale, Unrealized Loss of $160.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2023-08-10
- Trevi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-06-30 was $160.00K, a 18.52% increase year-over-year.
- Trevi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $34.00K.
- Trevi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was -$141.00K.
- Trevi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-09-30 was $128.00K.
- Trevi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $122.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2023-06-30 | $160.00K 10-Q · filed 2023-08-10 | $126.00K 10-Q · filed 2023-08-10 | $53.00K derived: sum of 3 quarters · filed 2023-08-10 | $181.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $34.00K 10-Q · filed 2023-05-11 | -$107.00K derived: sum of 2 quarters · filed 2023-05-11 | $21.00K derived: sum of 3 quarters · filed 2023-05-11 | $156.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-12-31 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$13.00K derived: sum of 2 quarters · filed 2023-03-16 | $122.00K derived: sum of 3 quarters · filed 2023-08-10 | $122.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $128.00K 10-Q · filed 2022-11-10 | $263.00K derived: sum of 2 quarters · filed 2023-08-10 | $263.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $135.00K 10-Q · filed 2023-08-10 | $135.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |